<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
"http://www.w3.org/TR/REC-html40/loose.dtd"> 
<html>
<head>
<title>Untitled Document</title>
<meta http-equiv="Content-Type" content="text/html;charset=utf-8">
</head>
<body>
<p>

# en/en-et.xml.gz<br>
# et/en-et.xml.gz

<p><hr>
(src)="1"> EPAR summary for the public <br>
(trg)="1"> Kokkuvõte üldsusele <br>
<hr>
(src)="2"> The European Commission granted a marketing authorisation valid throughout the EU for Improvac on 11 May 2009 . <br>
(trg)="2"> Euroopa Komisjon andis Improvaci müügiloa , mis kehtib kogu Euroopa Liidus , 11. mail 2009 . <br>
<hr>
(src)="3"> The full EPAR for Improvac can be found on the Agency 's website : ema.europa.eu / Find medicine / Veterinary medicines / European public assessment reports . <br>
(trg)="3"> Euroopa avaliku hindamisaruande täistekst Improvaci kohta on ameti veebilehel : ema.europa.eu / Find medicine / Veterinary medicines / European public assessment reports . <br>
<hr>
(src)="4"> The injection is given under the skin in the neck just behind the ear . <br>
(trg)="4"> Vaktsiini süstitakse kaelanaha alla , otse kõrva taha . <br>
<hr>
(src)="5"> Improvac must not be given to pigs by women who are or who may be pregnant . <br>
(trg)="5"> Improvaci ei tohi sigadele manustada naised , kes on või võivad olla rasedad . <br>
<hr>
(src)="6"> This summary was last updated in September 2017 . <br>
(trg)="6"> Kokkuvõtte viimane uuendus : 09-2017 . <br>
<hr>
(src)="7"> Improvac also reduces aggressive and sexual ( mounting ) behaviour in pigs . <br>
(trg)="7"> Improvac vähendab sigadel ka agressiivset ja seksuaalset käitumist ( selgatõusmine ) . <br>
<hr>
(src)="8"> What is the withdrawal period in food-producing animals ? <br>
(trg)="8"> Kui pikk on keeluaeg toiduloomadel ? <br>
<hr>
(src)="9"> It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union ( EU ) and its conditions of use . <br>
(trg)="9"> Selles selgitatakse , kuidas amet hindas veterinaarvaktsiini , et soovitada müügiloa andmist Euroopa Liidus ja kasutustingimusi . <br>
<hr>
(src)="10"> The Agency 's Committee for Medicinal Products for Veterinary Use ( CVMP ) concluded that Improvac 's benefits are greater than its risks and recommended that it be approved for use in the EU . <br>
(trg)="10"> Veterinaarravimite komitee järeldas , et Improvaci kasulikkus on suurem kui sellega kaasnevad riskid , ja soovitas vaktsiini kasutamise Euroopa Liidus heaks kiita . <br>
<hr>
(src)="11"> What is Improvac and what is it used for ? <br>
(trg)="11"> Mis on Improvac ja milleks seda kasutatakse ? <br>
<hr>
(src)="12"> The most common side effects with Improvac ( which may affect more than 1 in 10 pigs ) are injection site swelling , which gradually resolves but in 20 to 30 % of animals will last for more than 6 weeks , and a short-lived increase in body temperature of around 0.5 ˚ C within 24 hours of vaccination . <br>
(trg)="12"> Improvaci kõige sagedamad kõrvaltoimed ( võivad esineda enam kui 1 loomal 10st ) on süstekoha turse , mis taandub aja jooksul , kuid 20-30 % -l loomadest võib see püsida kauem kui 6 nädalat , ning lühiajaline kehatemperatuuri tõus ligikaudu 0,5 ° C võrra 24 tunni jooksul vaktsineerimisest . <br>
<hr>
(src)="13"> This is a summary of the European public assessment report ( EPAR ) for Improvac . <br>
(trg)="13"> See on vaktsiini Improvac Euroopa avaliku hindamisaruande kokkuvõte . <br>
<hr>
(src)="14"> Improvac starts to be effective within 1 week after the second injection . <br>
(trg)="14"> Improvaci toime avaldub 1 nädala jooksul pärast teist süstet . <br>
<hr>
(src)="15"> These may include a temporary reduction in sex hormone levels and reduced ability to reproduce in men and in women , including problems with pregnancy . <br>
(trg)="15"> Muu hulgas võib see ajutiselt vähendada suguhormoonide sisaldust ning meeste ja naiste viljakust , sh tekitada rasedusprobleeme . <br>
<hr>
(src)="16"> Why is Improvac approved ? <br>
(trg)="16"> Miks Improvac heaks kiideti ? <br>
<hr>
(src)="17"> Three field studies investigated the effectiveness of Improvac in reducing aggression and sexual behaviour in pigs . <br>
(trg)="17"> Kolmes väliuuringus uuriti Improvaci efektiivsust agressiivse ja seksuaalse käitumise vähendamisel . <br>
<hr>
(src)="18"> Improvac must only be used with a safety device including a needle guard and a mechanism to prevent accidental operation of the trigger . <br>
(trg)="18"> Improvaci peab kasutama üksnes koos ohutusseadmega , millel on nõelakaitse ja mehhanism , mis takistab päästiku juhuslikku vajutamist . <br>
<hr>
(src)="19"> The first injection is from 8 weeks of age and the second 4 to 6 weeks before slaughter . <br>
(trg)="19"> Esimene süst tehakse alates 8. elunädala vanuses ja teine 4-6 nädalat enne tapmist . <br>
<hr>
(src)="20"> Improvac is given to male pigs as two injections with at least a 4 week interval . <br>
(trg)="20"> Improvaci manustatakse kultidele kahe süstena , vähemalt 4-nädalase vaheajaga . <br>
<hr>
(src)="21"> The withdrawal period for meat from pigs treated with Improvac is ‘ zero ' days , which means there is no mandatory waiting time . <br>
(trg)="21"> Improvaciga vaktsineeritud sigade liha keeluaeg on 0 päeva , mis tähendab , et keeluaega ei ole . <br>
<hr>
(src)="22"> Improvac is used as an alternative to physical castration ( removal of the testes ) to reduce the presence of these compounds . <br>
(trg)="22"> Improvaci kasutatakse alternatiivina füüsilisele kastratsioonile ( munandite eemaldamisele ) , et vähendada nende ühendite sisaldust . <br>
<hr>
(src)="23"> It is not intended to provide practical advice on how to use Improvac . <br>
(trg)="23"> Hindamisaruandes ei anta Improvaci kasutamise praktilisi nõuandeid . <br>
<hr>
(src)="24"> Accidental self-injection of Improvac may produce similar effects in people to those seen in pigs . <br>
(trg)="24"> Improvaci juhuslik enesesüstimine võib tekitada inimesel sama reaktsiooni kui sigadel . <br>
<hr>
(src)="25"> The risk of these effects occurring is greater after a second or subsequent accidental injection than after a first injection . <br>
(trg)="25"> Nende nähtude tekkerisk on pärast teist või korduvat juhuslikku enesesüstimist suurem kui pärast esimest süstet . <br>
<hr>
(src)="26"> Boar taint is caused by the production and build-up of the natural compounds androstenone and skatole in the flesh of these animals . <br>
(trg)="26"> Kuldilõhna põhjustab looduslike ühendite androstenooni ja skatooli teke ja kogunemine nende loomade lihas- ja rasvkoes . <br>
<hr>
(src)="27"> Two studies showed reduction of aggression and mounting from 1 to 2 weeks after the second injection of Improvac , while the third studied the long term effect on aggression and mounting after 4 weeks only . <br>
(trg)="27"> Kahes uuringus vähenes sigadel agressiivne käitumine ja selgatõusmine 1-2 nädala möödudes teisest Improvaci süstest ning kolmandas uuringus vaadeldi pikaajalist toimet agressiivsele käitumisele ja selgatõusmisele üksnes pärast 4 nädalat . <br>
<hr>
(src)="28"> The withdrawal period is the time required after administration of a medicine before an animal can be slaughtered and the meat used for human consumption . <br>
(trg)="28"> Keeluaeg on alates vaktsiini manustamisest arvestatav aeg , mille jooksul ei tohi looma tappa ega tema liha inimtoiduks tarvitada . <br>
<hr>
(src)="29"> For the full list of restrictions and all side effects reported with Improvac , see the package leaflet . <br>
(trg)="29"> Improvaci kohta teatatud piirangute ja kõrvaltoimete täielik loetelu on pakendi infolehel . <br>
<hr>
(src)="30"> Androstenone and skatole levels are reduced from 4 to 6 weeks after the second injection and reduction of aggression and sexual behaviour is seen from 1 to 2 weeks after the second injection . <br>
(trg)="30"> Androstenooni- ja skatoolisisaldus väheneb 4-6 nädala möödudes teisest süstest ning agressiivne ja seksuaalne käitumine 1-2 nädala möödudes teisest süstest . <br>
<hr>
(src)="31"> Other information about Improvac ? <br>
(trg)="31"> Muu teave Improvaci kohta <br>
<hr>
(src)="32"> The levels of antibodies decline with time but are still high enough to be reliably effective 4 to 6 weeks after the second injection . <br>
(trg)="32"> Aja jooksul antikehade sisaldus väheneb , ent on sellegipoolest piisavalt suur , et toime püsiks 4-6 nädala jooksul pärast teist süstet . <br>
<hr>
(src)="33"> What are the risks associated with Improvac ? <br>
(trg)="33"> Mis riskid Improvaciga kaasnevad ? <br>
<hr>
(src)="34"> In case of accidental self-injection , medical advice should be sought immediately and the package leaflet or label shown to the doctor . <br>
(trg)="34"> Juhusliku enesesüstimise korral tuleb pöörduda otsekohe arsti poole ja näidata talle pakendi infolehte või etiketti . <br>
<hr>
(src)="35"> Special care should be taken to avoid accidental self-injection . <br>
(trg)="35"> Juhuslikku enesesüstimist tuleb väga hoolikalt vältida . <br>
<hr>
(src)="36"> In case of skin or eye contact the affected area should be rinsed immediately with water . <br>
(trg)="36"> Vaktsiini juhuslikul sattumisel nahale või silma tuleb seda kohta otsekohe pesta veega . <br>
<hr>
(src)="37"> In addition Improvac treated pigs had reduced blood levels of testosterone . <br>
(trg)="37"> Peale selle oli Improvaciga vaktsineeritud sigadel vere testosteroonisisaldus väiksem . <br>
<hr>
(src)="38"> Safety information has been included in the summary of product characteristics and the package leaflet for Improvac , including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers . <br>
(trg)="38"> Ravimi omaduste kokkuvõttesse ja pakendi infolehele lisati Improvaci ohutusteave , kus on ka tervishoiuspetsialistide ja loomaomanike või -pidajate võetavad meetmed . <br>
<hr>
(src)="39"> The first injection had a limited effect , but the second injection is followed by production of antibodies against GnRF . <br>
(trg)="39"> Uuringutes tõendati , et esimese süste toime on piiratud , ent teise süste järel tekivad GnRF-vastased antikehad . <br>
<hr>
(src)="40"> Improvac is a veterinary medicine used in male pigs to reduce ‘ boar taint ' in the meat obtained from them after slaughter . <br>
(trg)="40"> Improvac on veterinaarvaktsiin , mida kasutatakse kultidel , et vähendada kuldilõhna lihal , mida saadakse loomadelt pärast tapmist . <br>
<hr>
(src)="41"> What are the precautions for the person who gives the medicine or comes into contact with the animal ? <br>
(trg)="41"> Milliseid ettevaatusmeetmeid peab võtma loomale vaktsiini andev või loomaga kokku puutuv inimene ? <br>
<hr>
(src)="42"> Boar taint is the offensive odour or taste which may be present in pork or pork products from non-castrated mature male pigs . <br>
(trg)="42"> Kuldilõhn on ebameeldiv lõhn või maitse , mis võib esineda kastreerimata suguküpsete kultide lihal või nende lihast valmistatud toodetel . <br>
<hr>
(src)="43"> This temporarily inhibits release of steroids from the testicles , including androstenone , one of the two causes of boar taint . <br>
(trg)="43"> Sellega pärsib Improvac ajutiselt steroidide , sealhulgas androstenooni ( üks kahest kuldilõhna põhjustavast looduslikust ühendist ) vabastamist munanditest . <br>
<hr>
(src)="44"> Skatole , the other major cause of boar taint , is produced in the intestines and levels are reduced since the reduced level of sex hormones allows the liver to metabolise ( break it down ) more efficiently . <br>
(trg)="44"> Teine kuldilõhna põhjustav looduslik ühend skatool tekib soolestikus ning skatoolisisaldus väheneb selle tõttu , et suguhormoonide sisalduse vähenemise tulemusena suudab maks skatooli tõhusamalt metaboliseerida ( lagundada ) . <br>
<hr>
(src)="45"> The active substance in Improvac is an analogue of ( similar to ) gonatadotropin releasing factor ( GnRF ) linked to a carrier protein obtained from the bacterium Corynebacterium diphtheriae . <br>
(trg)="45"> Improvaci toimeaine on gonadotropiini vabastava faktori ( GnRF ) analoog ( sarnane aine ) , mis on seotud bakterist Corynebacterium diphtheriae saadud kandevalguga . <br>
<hr>
(src)="46"> How is Improvac used ? <br>
(trg)="46"> Kuidas Improvaci kasutatakse ? <br>
<hr>
(src)="47"> For practical information about using Improvac , animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist . <br>
(trg)="47"> Kui loomaomanikud või -pidajad vajavad Improvaci kasutamise praktilisi nõuandeid , peavad nad lugema pakendi infolehte või pöörduma oma veterinaararsti või apteekri poole . <br>
<hr>
(src)="48"> In a number of field studies pigs treated with Improvac were comparable to surgically castrated pigs in terms of levels of androstenone and skatole at slaughter . <br>
(trg)="48"> Mitmes väliuuringus oli Improvaciga vaktsineeritud sigade androstenooni- ja skatoolisisaldus tapmisel võrreldav androstenooni- ja skatoolisisaldusega kirurgiliselt kastreeritud sigadel . <br>
<hr>
(src)="49"> Improvac works by stimulating the pig 's immune system to produce antibodies against gonadotropin-releasing hormone ( GnRH ) , part of the system that controls sexual development . <br>
(trg)="49"> Improvac stimuleerib sea immuunsüsteemi tootma antikehi gonadotropiini vabastava hormooni ( GnRH ) vastu , mis reguleerib immuunsüsteemis sugulist arengut . <br>
<hr>
(src)="50"> Improvac gonadotropin releasing factor ( GnRF ) analogue-protein conjugate <br>
(trg)="50"> Improvac gonadotropiini vabastava faktori ( GnRF ) analoogvalgu konjugaat <br>
<hr>
(src)="51"> Improvac is available as a solution for injection and can only be obtained with a prescription . <br>
(trg)="51"> Improvaci turustatakse süstelahusena ja see on retseptivaktsiin . <br>
<hr>
(src)="52"> What benefits of Improvac have been shown in studies ? <br>
(trg)="52"> Milles seisneb uuringute põhjal Improvaci kasulikkus ? <br>
<hr>
(src)="53"> Improvac also contains a compound derived from the sugar dextran as an adjuvant ( ingredient that strengthens the immune response ) . <br>
(trg)="53"> Improvac sisaldab immuunvastuse tugevdamiseks ka adjuvanti ( dekstraani ( teatud suhkur ) derivaat ) . <br>
<hr>
(src)="54"> For further information , see the package leaflet . <br>
(trg)="54"> Üksikasjalik teave on pakendi infolehel . <br>
<hr>
(src)="55"> Improvac must not be given to female pigs or to male pigs intended for breeding . <br>
(trg)="55"> Improvaci ei tohi kasutada emistel ega kultidel , keda kavatsetakse kasutada tõuaretuseks . <br>
<hr>
(src)="56"> Improvac contains the active substance gonadotropin releasing factor ( GnRF ) analogue-protein conjugate . <br>
(trg)="56"> Improvac sisaldab toimeainena gonadotropiini vabastava faktori ( GnRF ) analoogvalgu konjugaati . <br>
<hr>
(src)="57"> How does Improvac work ? <br>
(trg)="57"> Kuidas Improvac toimib ? <br>
<hr>
(src)="58"> This summary was last updated in 05-2012 . <br>
(trg)="58"> Kokkuvõtte viimane uuendus : 05-2012 <br>
<hr>
(src)="59"> The European Commission granted a marketing authorisation valid throughout the European Union for Preotact on 24 April 2006 . <br>
(trg)="59"> Euroopa Komisjon andis Preotacti müügiloa , mis kehtib kogu Euroopa Liidu territooriumil , 24. aprillil 2006 . <br>
<hr>
(src)="60"> It must also not be used in patients : <br>
(trg)="60"> Ravimit ei tohi kasutada patsiendid , <br>
<hr>
(src)="61"> The full EPAR for Preotact can be found on the Agency 's website : ema.europa.eu / Find medicine / Human medicines / European Public Assessment Reports . <br>
(trg)="61"> Euroopa avaliku hindamisaruande täistekst Preotacti kohta on ameti veebilehel : ema.europa.eu / Find medicine / Human medicines / European Public Assessment Reports . <br>
<hr>
(src)="62"> Other information about Preotact <br>
(trg)="62"> Muu teave Preotacti kohta <br>
<hr>
(src)="63"> About two-thirds of the women continued taking Preotact for up to two years , and their bone density was measured . <br>
(trg)="63"> Ligikaudu kaks kolmandikku naistest jätkas Preotacti kasutamist kuni kahe aasta jooksul , mille järel mõõdeti nende luutihedust . <br>
<hr>
(src)="64"> The main measure of effectiveness was the rate of vertebral fractures after 18 months of treatment . <br>
(trg)="64"> Efektiivsuse põhinäitaja oli lülisambamurdude osakaal 18kuulise ravi järel . <br>
<hr>
(src)="65"> The risk reduction was higher in women who already had a fractured vertebra in the past , and in women whose score for spine bone density was already low at the start of the study , indicating that they had a more fragile spine . <br>
(trg)="65"> Risk vähenes rohkem naistel , kellel oli varem esinenud lülisambamurd , ja naistel , kelle lülisambaluu tihedusenäit oli juba uuringu alguses madal , viidates hapramale lülisambale . <br>
<hr>
(src)="66"> The bone density was also the main measure in another study , which looked at the use of Preotact with or without alendronate ( a bisphosphonate ) . <br>
(trg)="66"> Luutihedus oli peamine näitaja ka teises uuringus , milles vaadeldi Preotacti kasutamist koos alendronaadiga ( bisfosfonaat ) või ilma selleta . <br>
<hr>
(src)="67"> Preotact parathyroid hormone <br>
(trg)="67"> Preotact paratüreoidhormoon <br>
<hr>
(src)="68"> Patients may inject themselves once they have been trained ( a user manual is supplied ) . <br>
(trg)="68"> Patsiendid võivad ennast ise süstida , kui nad on seda õppinud ( kaasas on kasutusõpetus ) . <br>
<hr>
(src)="69"> The CHMP decided that Preotact 's benefits are greater than its risks and recommended that it be given marketing authorisation . <br>
(trg)="69"> Inimravimite komitee otsustas , et Preotacti kasulikkus on suurem kui sellega kaasnevad riskid , ja soovitas anda ravimi müügiloa . <br>
<hr>
(src)="70"> Preotact has been studied in one main study involving 2,532 women with postmenopausal osteoporosis . <br>
(trg)="70"> Preotacti toimet on uuritud ühes põhiuuringus , milles osales 2532 menopausijärgses eas osteoporoosiga naist . <br>
<hr>
(src)="71"> Preotact significantly reduced the risk of having a vertebral fracture , in comparison with placebo : after 18 months , there were 42 vertebral fractures in the placebo group ( 3.37  ) and 17 in the Preotact group ( 1.32  ) . <br>
(trg)="71"> Võrreldes platseeboga vähendas Preotact märkimisväärselt lülisambamurru riski : pärast 18kuulist ravi oli platseeborühmas 42 lülisambamurru juhtu ( 3,37 % ) ja Preotacti rühmas 17 juhtu ( 1,32 % ) . <br>
<hr>
(src)="72"> • who have a bone disease that is not osteoporosis , <br>
(trg)="72"> • kellel on muu luuhaigus , mis ei ole osteoporoos ; <br>
<hr>
(src)="73"> It also increases the absorption of calcium from food and prevents too much calcium from being lost in the urine . <br>
(trg)="73"> Ravim suurendab ka kaltsiumi imendumist toidust ning takistab liiga suure kaltsiumikoguse eritumist uriiniga . <br>
<hr>
(src)="74"> Gradually , the bones become thin and fragile , and more likely to break ( fracture ) . <br>
(trg)="74"> Luud muutuvad järk-järgult urbsemaks ja hapramaks ning murduvad kergesti . <br>
<hr>
(src)="75"> It is produced by a method known as ‘ recombinant DNA technology ' : the hormone is made by a bacterium that has received a gene ( DNA ) that makes it able to produce it . <br>
(trg)="75"> Seda toodetakse rekombinant-DNA-tehnikana tuntud meetodil : hormooni toodab bakter , millele on lisatud selle teket võimaldav geen ( DNA ) . <br>
<hr>
(src)="76"> For more information about treatment with Preotact , read the package leaflet ( also part of the EPAR ) or contact your doctor or pharmacist . <br>
(trg)="76"> Kui vajate Preotactiga toimuva ravi kohta lisateavet , lugege palun pakendi infolehte ( mis on samuti Euroopa avaliku hindamisaruande osa ) või pöörduge oma arsti või apteekri poole . <br>
<hr>
(src)="77"> What is the risk associated with Preotact ? <br>
(trg)="77"> Mis riskid Preotactiga kaasnevad ? <br>
<hr>
(src)="78"> This is a summary of the European public assessment report ( EPAR ) for Preotact . <br>
(trg)="78"> See on ravimi Preotact Euroopa avaliku hindamisaruande kokkuvõte . <br>
<hr>
(src)="79"> Increases in bone density were also seen during the study . <br>
(trg)="79"> Uuringu käigus tuvastati ka luutiheduse suurenemine . <br>
<hr>
(src)="80"> The study of Preotact with alendronate showed that using alendronate after Preotact can bring further increases in bone density . <br>
(trg)="80"> Preotacti ja alendronaadi uuring näitas , et alendronaadi kasutamine pärast Preotacti võib luutihedust veelgi suurendada . <br>
<hr>
(src)="81"> The most common side effects with Preotact ( seen in more than 1 patient in 10 ) are hypercalcaemia ( high blood calcium levels ) , hypercalciuria ( high calcium levels in the urine ) and nausea ( feeling sick ) . <br>
(trg)="81"> Preotacti kõige sagedamad kõrvalnähud ( esinenud enam kui 1 patsiendil 10st ) on hüperkaltseemia ( vere suur kaltsiumisisaldus ) , hüperkaltsiuuria ( kaltsiumirohkus uriinis ) ja iiveldus . <br>
<hr>
(src)="82"> It explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Preotact . <br>
(trg)="82"> Selles selgitatakse , kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist ; samuti esitatakse komitee soovitused , kuidas ravimit kasutada . <br>
<hr>
(src)="83"> When the cartridge is inserted in the special injection pen and the pen screwed together , or when the pre-filled pen is prepared for use , the powder and solvent mix to make up the solution for injection . <br>
(trg)="83"> Kui kolbampulli sisu sisestatakse spetsiaalsesse pensüstlisse ja pensüstel keeratakse kokku või kui eeltäidetud pensüstel seatakse kasutusvalmis , siis pulber ja lahusti segunevad ja moodustavad süstelahuse . <br>
<hr>
(src)="84"> Preotact was compared with placebo ( a dummy treatment ) . <br>
(trg)="84"> Preotacti võrreldi platseeboga ( näiv ravim ) . <br>
<hr>
(src)="85"> Preotact must not be used in people who are hypersensitive ( allergic ) to parathyroid hormone or any of the other ingredients . <br>
(trg)="85"> Preotacti ei tohi kasutada inimesed , kes on paratüreoidhormooni või ravimi mis tahes muu koostisaine suhtes ülitundlikud ( allergilised ) . <br>
<hr>
(src)="86"> The parathyroid hormone in Preotact is identical to the human parathyroid hormone . <br>
(trg)="86"> Preotactis sisalduv paratüreoidhormoon on identne inimese paratüreoidhormooniga . <br>
<hr>
(src)="87"> Osteoporosis happens when not enough new bone grows to replace the bone that is naturally broken down . <br>
(trg)="87"> Osteoporoos tekib , kui loomulikul teel laguneva luukoe asemele ei kasva piisavalt uut luukude . <br>
<hr>
(src)="88"> Osteoporosis is more common in women after the menopause , when the levels of the female hormone oestrogen fall . <br>
(trg)="88"> Osteoporoos on sagedam naistel pärast menopausi , kui naissuguhormooni östrogeeni sisaldus väheneb . <br>
<hr>
(src)="89"> • who have bone cancer or cancer that has spread to the bones , <br>
(trg)="89"> • kellel on luuvähk või luudesse levinud vähk ; <br>
<hr>
(src)="90"> Preotact has been shown to significantly reduce vertebral ( spine ) fractures , but not hip fractures . <br>
(trg)="90"> On tõestatud , et Preotact vähendab oluliselt lülisambamurde , kuid mitte puusamurde . <br>
<hr>
(src)="91"> What is Preotact ? <br>
(trg)="91"> Mis on Preotact ? <br>
<hr>
(src)="92"> The recommended dose of Preotact is 100 micrograms , given once a day as an injection under the skin into the abdomen . <br>
(trg)="92"> Soovituslik annus on 100 mikrogrammi Preotacti manustatuna üks kord ööpäevas subkutaanse ( nahaaluse ) süstina kõhupiirkonda . <br>
<hr>
(src)="93"> Preotact is a medicine that contains the active substance parathyroid hormone . <br>
(trg)="93"> Preotact on ravim , mis sisaldab toimeainena paratüreoidhormooni . <br>
<hr>
(src)="94"> • who are having or have had radiation therapy to the skeleton , <br>
(trg)="94"> • kes saavad või on saanud luustiku kiiritusravi ; <br>
<hr>
(src)="95"> • who have any disorder that affects the calcium and phosphate balance in the body , <br>
(trg)="95"> • kellel on häire , mis mõjutab organismi kaltsiumitasakaalu ; <br>
<hr>
(src)="96"> Patients may also need to take calcium and vitamin D supplements if they do not have enough from their diet . <br>
(src)="97"> Preotact can be used for up to 24 months , after which patients can be treated with a bisphosphonate ( a medicine that reduces bone loss ) . <br>
(trg)="96"> Preotacti tohib kasutada kuni 24 kuud ja seejärel tohib patsiente ravida bisfosfonaatidega ( ravim , mis vähendab luukoe hävimist ) . <br>
<hr>
(src)="98"> Preotact contains parathyroid hormone , which stimulates bone formation by acting on osteoblasts ( bone forming cells ) . <br>
(trg)="97"> Preotact sisaldab paratüreoidhormooni , mis avaldab toimet osteoblastidele ( luukude moodustavatele rakkudele ) , stimuleerides luu moodustumist . <br>
<hr>
(src)="99"> Preotact is used for the treatment of osteoporosis ( a disease that makes bones fragile ) in postmenopausal women who are at high risk of fractures . <br>
(trg)="98"> Preotacti kasutatakse osteoporoosi ( luu-urbnemise ) raviks menopausijärgsetel naistel , kellel on kõrge luumurrurisk . <br>
<hr>
(src)="100"> Why has Preotact been approved ? <br>
(trg)="99"> Miks Preotact heaks kiideti ? <br>
<hr>
(src)="101"> The medicine can only be obtained with a prescription . <br>
(trg)="100"> Preotact on retseptiravim . <br>
<hr>
</body>
</html>
